Copyright © 2004 by the European Society of Cardiology.
Clinical research
Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset
a Department of Internal Medicine/Cardiology, Krankenhaus Barmherzige Schwestern, Seilerstätte 4, A-4020 Linz, Austria
b Department of Internal Medicine/Cardiology, Krankenanstalt Rudolfstiftung, Vienna Austria
c Department of Internal Medicine, Krankenhaus Sierning, Austria
d Department of Internal Medicine, Krankenhaus Braunau, Austria
e Department of Internal Medicine, Krankenhaus Barmherzige Schwestern, Ried, Austria
f Department of Internal Medicine, Landeskrankenhaus Enns, Austria
g Department of Internal Medicine, Bezirkskrankenhaus Hall/Tirol, Austria
h Department of Medical Computer Sciences, Section of Clinical Biometrics, University of Vienna, Austria
Received November 26, 2003;
revised February 4, 2004;
accepted April 29, 2004
* Corresponding author. Tel.: +43-732-7677-7202; fax: +43-732-7677-7414
E-mail address: johann.reisinger{at}bhs.at
See page 1274 for the editorial comment on this article1
Aims This study compared the efficacy and safety of intravenous flecainide and ibutilide for immediate cardioversion of atrial fibrillation (AF).
Methods and results We conducted a prospective, randomised trial, including 207 patients with AF of recent onset (
48 h). Flecainide was given over 20 min at a dose of 2 mg/kg body weight (maximum 200 mg), ibutilide was infused at a dose of 1 mg (or 0.01 mg/kg if less than 60 kg) over 10 min, followed by a 10 min observation period and an identical second dose if AF did not convert to sinus rhythm (SR). Treatment was considered successful if SR occurred within 90 min of starting medication. The conversion rates were 56.4% in patients given flecainide and 50.0% in patients given ibutilide 
. Multivariate analysis revealed that a lower age for women independently increased the probability of conversion. None of the other variables, including left atrial size, left ventricular systolic function, presence of left ventricular hypertrophy, plasma levels of potassium or magnesium at baseline, or concomitant use of digoxin, beta-blocker, diltiazem or verapamil were predictors of conversion. The frequency of adverse events was comparable in the two treatment groups.
Conclusions There was no significant difference in the cardioversion efficacy or in the risk of adverse events between flecainide and ibutilide in patients with AF of recent onset. In patients without contraindications to both medications, the physician's choice has to be governed by other factors.
Key Words: Atrial fibrillation • Cardioversion • Flecainide • Ibutilide
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Pharmacological cardioversion of recent onset atrial fibrillation
- Ijaz A Khan
EHJ 2004 25: 1274-1276.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  Y. Blaauw, U. Schotten, A. van Hunnik, H.R. Neuberger, and M.A. Allessie Cardioversion of persistent atrial fibrillation by a combination of atrial specific and non-specific class III drugs in the goat Cardiovasc Res, July 1, 2007; 75(1): 89 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O Viktorsdottir, A Henriksdottir, and D O Arnar Ibutilide for treatment of atrial fibrillation in the emergency department Emerg. Med. J., February 1, 2006; 23(2): 133 - 134. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. A Khan Pharmacological cardioversion of recent onset atrial fibrillation Eur. Heart J., August 1, 2004; 25(15): 1274 - 1276. [Full Text] [PDF]
|
|